Table 5

Comparison of treatment data between lupus nephritis patients with and without renal TMA

LN with renal TMA

LN without renal TMA

P-value

Number of patients (%)

36

112

Treatment

PE (Number of patients (%))

19 (52.8)

7 (6.25)

<0.001

MP (Number of patients (%))

26 (72.2)

18 (16.1)

<0.001

P

36 (100)

112 (100)

1

CYC

30 (83.3)

88 (78.6)

0.536

AZA

1 (2.8)

5 (4.5)

1

MMF

3 (83.3)

11 (9.8)

1

LEF

2 (5.6)

8 (7.1)

1

Treatment response

CR

8 (22.2)

30 (26.8)

0.586

PR

12 (33.3)

65 (58.0)

0.01

TF

16 (44.4)

17 (15.2)

<0.001

Duration of follow-up (m)

53 (6,240)

53 (6,282)

0.15

Relapse rate

4 (4/20, 20%, 3 with nephritic relapse and 1 with proteinuric relapse)

17 (17/95, 17.89%, 15 with nephritic relapse and 2 with proteinuric relapse)

0.543

AZA, azathioprine; CR, complete remission; CYC, cyclophosphamide; LEF, leflunomide; MMF, mycophenolate mofetil; MP, methylprednisolone impulse; P, oral prednisone; PE, plasma exchange; PR, partial remission; TF, treatment failure

Song et al. Arthritis Research & Therapy 2013 15:R12   doi:10.1186/ar4142